EIT Pharma announced on August 11, 2026, that the US Food and Drug Administration (FDA) accepted its new drug application (NDA) for lonafarnib as a treatment for chronic hepatitis D (CHD), although it did not disclose an FDA action date, planned advisory committee review, proposed treatment regimen, or requested labeling in its announcement.1
"FDA acceptance of our NDA is an important milestone in our mission to bring a potential new oral treatment to people living with chronic hepatitis D," said Leen Kawas, PhD, chief executive officer of EIT Pharma, in a statement.1
Key Facts
Drug: Lonafarnib, oral investigational therapy
Indication: Chronic hepatitis D
Status: NDA accepted by FDA
Evidence: Phase 3 D-LIVR; >400 patients
Primary end point: ≥2-log decline in HDV RNA plus ALT normalization at week 48 vs placebo — met with statistical significance in 2022 topline data2
Results: Updated efficacy and safety figures not released with NDA acceptance
CHD occurs in individuals with hepatitis B virus infection and can progress to cirrhosis, liver failure, hepatocellular carcinoma, and death. No oral therapy is currently FDA approved for CHD in the United States. Lonafarnib remains investigational and is not approved by the FDA or another regulatory authority for this indication.1
What the Phase 3 D-LIVR Trial Evaluated
The NDA is supported primarily by the global, randomized, placebo-controlled phase 3 D-LIVR study, described by EIT Pharma as the largest clinical trial conducted in CHD to date. The study enrolled >400 patients across 21 countries and evaluated lonafarnib-based regimens over 48 weeks.2 The submission also includes phase 1 and 2 clinical findings, nonclinical evidence, and manufacturing information.1
D-LIVR's composite primary end point was a ≥2-log decline in HDV RNA combined with normalization of alanine aminotransferase (ALT) at week 48 compared with placebo; topline data reported in 2022 by original trial sponsor Eiger BioPharmaceuticals indicated that both lonafarnib-based regimens met this end point with statistical significance versus placebo.2
The current NDA announcement did not provide participant characteristics, dosing group breakdowns, comparator details beyond placebo control, updated statistical analysis, or numerical efficacy results. It also did not report adverse event rates, treatment discontinuations, laboratory abnormalities, serious adverse events, or deaths.